Unterberg Capital LLC acquired a new stake in Cascadian Therapeutics Inc (NASDAQ:CASC) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 100,000 shares of the biopharmaceutical company’s stock, valued at approximately $370,000. Cascadian Therapeutics makes up about 0.5% of Unterberg Capital LLC’s holdings, making the stock its 29th largest holding. Unterberg Capital LLC owned about 0.20% of Cascadian Therapeutics as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors have also added to or reduced their stakes in the company. BlackRock Inc. boosted its position in Cascadian Therapeutics by 35.9% during the fourth quarter. BlackRock Inc. now owns 2,729,571 shares of the biopharmaceutical company’s stock worth $10,100,000 after purchasing an additional 720,462 shares during the period. Essex Investment Management Co. LLC bought a new position in shares of Cascadian Therapeutics in the fourth quarter valued at approximately $567,000. Alps Advisors Inc. bought a new position in shares of Cascadian Therapeutics in the fourth quarter valued at approximately $207,000. SG Americas Securities LLC boosted its position in shares of Cascadian Therapeutics by 194.7% in the fourth quarter. SG Americas Securities LLC now owns 38,541 shares of the biopharmaceutical company’s stock valued at $143,000 after acquiring an additional 25,464 shares during the period. Finally, Dimensional Fund Advisors LP lifted its position in Cascadian Therapeutics by 423.0% during the third quarter. Dimensional Fund Advisors LP now owns 511,899 shares of the biopharmaceutical company’s stock valued at $2,094,000 after purchasing an additional 414,019 shares during the last quarter. 81.38% of the stock is currently owned by hedge funds and other institutional investors.
Several research analysts have commented on CASC shares. Zacks Investment Research downgraded shares of Cascadian Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, January 9th. Raymond James Financial downgraded shares of Cascadian Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 31st. BidaskClub raised shares of Cascadian Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, January 31st. ValuEngine upgraded shares of Cascadian Therapeutics from a “strong sell” rating to a “sell” rating in a report on Wednesday, January 31st. Finally, Cantor Fitzgerald set a $10.00 price target on shares of Cascadian Therapeutics and gave the stock a “hold” rating in a research note on Friday, March 9th. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $6.17.
COPYRIGHT VIOLATION NOTICE: This article was first posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this article on another publication, it was stolen and reposted in violation of US and international copyright law. The original version of this article can be viewed at https://stocknewstimes.com/2018/03/14/unterberg-capital-llc-invests-370000-in-cascadian-therapeutics-inc-casc.html.
Cascadian Therapeutics Profile
Cascadian Therapeutics, Inc, formerly Oncothyreon Inc, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor.
Receive News & Ratings for Cascadian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cascadian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.